Japan Health Insurance Amendment Bill Enters Deliberation on OTC Drug Co-payments
A bill to amend Japan's Health Insurance Act has entered substantive deliberation in the House of Representatives' Health, Labor and Welfare Committee. The proposed legislation introduces a system requiring patients prescribed 'OTC similar drugs'—prescription medications with ingredients identical to over-the-counter products—to pay additional co-payments. The government aims to implement this measure by March 2027 to address rising healthcare costs and encourage the use of cheaper over-the-counter alternatives. However, exemptions are planned for vulnerable groups, including children, low-income individuals, hospitalized patients, and those with chronic diseases such as cancer or intractable conditions, provided a doctor deems the prescription medically necessary. A key point of contention remains the precise definition of eligible exemptions. The Ministry of Health, Labor and Welfare stated that an expert review meeting will be convened after the law's enactment to determine specific targets and criteria. This move reflects ongoing efforts to reform social security and manage national health insurance finances while balancing patient access to necessary treatments.
Wire timeline
Japan Health Insurance Amendment Bill Enters Deliberation on OTC Drug Co-payments
A bill to amend Japan's Health Insurance Act has entered substantive deliberation in the House of Representatives' Health, Labor and Welfare Committee. The proposed legislation introduces a system requiring patients prescribed 'OTC similar drugs'—prescription medications with ingredients identical to over-the-counter products—to pay additional co-payments. The government aims to implement this measure by March 2027 to address rising healthcare costs and encourage the use of cheaper over-the-counter alternatives. However, exemptions are planned for vulnerable groups, including children, low-income individuals, hospitalized patients, and those with chronic diseases such as cancer or intractable conditions, provided a doctor deems the prescription medically necessary. A key point of contention remains the precise definition of eligible exemptions. The Ministry of Health, Labor and Welfare stated that an expert review meeting will be convened after the law's enactment to determine specific targets and criteria. This move reflects ongoing efforts to reform social security and manage national health insurance finances while balancing patient access to necessary treatments.
asahi